Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202...
Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9349 4906
Fax: 61 3 9349 4906
Address:
350 Collins Street, Suite 4 Level 14, Melbourne, Australia
